Karo Bio announces clinical phase II results of thyroid hormone analog eprotirome

NewsGuard 100/100 Score
Sep 24 2009

The Swedish biotech company Karo Bio (Reuters: KARO.ST) (STO:KARO) today announced that results from a clinical phase II study of the company’s thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.

The presentation will be made by Professor Paul W Ladenson from the Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, at the 80th Annual Meeting of the American Thyroid Association (ATA), held September 23-27, 2009, at the Breakers Hotel, Palm Beach, Florida, US.

The presentation will take place on September 26, at 3:30 pm US Eastern Time (EST) / 9:30 pm Central European Time (CET).

http://www.karobio.com/

Posted in: Drug Trial News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Low-risk differentiated thyroid cancer patients in the U. S. experience lower rates of mortality
Long-term use of certain progestogen drugs may raise risk of intracranial meningioma
Relugolix and radiation therapy may be a safe, effective combination for treating prostate cancer
Popular diabetes drugs not linked to thyroid cancer risk, study finds
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels
European Hormone Day 2024 puts spotlight on the vital role of hormones in chronic diseases
New treatment approach improves recurrence-free survival in early breast cancer patients
Understanding the genetics behind thyroid cancer to prevent unnecessary invasive treatments

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study provides reassurance regarding the safety of using hormone therapy after age 65 years